First- and Second-Line Treatment Options in Lower-Risk MDS

Video

Hematologic oncology experts give an overview of first- and second-line treatment options for lower-risk myelodysplastic syndromes.

Related Videos
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Debu Tripathy, MD
Zeynep Eroglu, MD
Scott Kopetz, MD, PhD, FACP
Ibrahim Aldoss, MD
Scott Kopetz, MD, PhD, FACP
Related Content
Angelos Stergiou, MD, ScD hc

SLS009 Plus Venetoclax/Azacitidine Produces Responses in R/R AML, Including ASXL1+ Disease

May 1st 2024
Article
Amin Nassar, MD, hematology/oncology fellow, Yale University; Elias Bou Farhat, MD, postdoctoral research fellow, Department of Medicine, Brigham and Women’s Hospital

Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

April 29th 2024
Podcast
Samer A. Srour, MB ChB, MS

Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC

April 29th 2024
Article
Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

FDA Approval Insights: Ponatinib in Ph+ ALL

April 8th 2024
Podcast
State of the Science Summit - Hematologic Malignancies: Chaired by Catherine E. Lai, MD, MPH

State of the Science Summit - Hematologic Malignancies: Chaired by Catherine E. Lai, MD, MPH

April 25th 2024
Article
He Huang, MD, PhD, of First Affiliated Hospital, Zhejiang University School of Medicine

CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies

April 24th 2024
Article